<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7523</journal-id>
<journal-title><![CDATA[Revista Cubana de Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Cuban de Med]]></abbrev-journal-title>
<issn>0034-7523</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-75232024000100017</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Trasplante de progenitores hematopoyéticos autólogo en pacientes con mieloma múltiple]]></article-title>
<article-title xml:lang="en"><![CDATA[Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez Rosales]]></surname>
<given-names><![CDATA[Carlos Lázaro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carnot Uria]]></surname>
<given-names><![CDATA[José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández Cruz]]></surname>
<given-names><![CDATA[Calixto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Muñío Perurena]]></surname>
<given-names><![CDATA[Jorge Ernesto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pardo Ramírez]]></surname>
<given-names><![CDATA[Ibis Karina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Llauger]]></surname>
<given-names><![CDATA[Kali Cepero]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García García]]></surname>
<given-names><![CDATA[Aliette]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez Fraga]]></surname>
<given-names><![CDATA[Yusaima]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Clínico Quirúrgico Docente Hermanos Ameijeiras  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>63</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0034-75232024000100017&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0034-75232024000100017&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0034-75232024000100017&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: El trasplante de progenitores hematopoyéticos autólogo forma parte de los avances en la terapéutica de pacientes con diagnóstico del mieloma múltiple durante los últimos años.  Objetivo: Evaluar los resultados del trasplante de progenitores hematopoyéticos autólogo en pacientes con mieloma múltiple.  Métodos: Se realizó un estudio descriptivo, retrospectivo y de cohorte, conformándose una muestra de 15 pacientes atendidos en el Servicio de Hematología del Hospital Clínico Quirúrgico Hermanos Ameijeiras durante el período comprendido de noviembre de 2009 a noviembre de 2019.  Resultados: En el estudio realizado la edad promedio fue de 54,67 años; el 53,3 % fue del sexo masculino y todos debutaron en estadio III de Durie-Salmon. Como acondicionamiento para el trasplante el 67,7 % recibió altas dosis de melfalán en dosis de 200 mg/m2. Las citopenias y la toxicidad gastrointestinal fueron las complicaciones más frecuentes (93,3 %). La recuperación de las cifras de neutrófilos y plaquetas ocurrió como promedio a los 11 días. Solo dos pacientes fallecieron (13,3 %) y 13 (86,7 %) se encuentran en remisión completa con una probabilidad de sobrevida global a los 5 años, el 77,8 %.  Conclusiones: El trasplante de progenitores hematopoyéticos autólogo con el empleo de altas dosis de melfalán como acondicionamiento en pacientes con mieloma múltiple es un proceder realizable con una mortalidad relativamente baja y demuestra que su inclusión en el tratamiento de los pacientes mejora considerablemente sus expectativas de sobrevida.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: Autologous hematopoietic stem cell transplantation is part of the advances in the treatment of patients diagnosed with multiple myeloma in recent years.  Objective: To evaluate the results of autologous hematopoietic stem cell transplantation in patients with multiple myeloma.  Methods: A descriptive, retrospective and cohort study was carried out, forming a sample of 15 patients treated in the Hematology Service at Hermanos Ameijeiras Clinical Surgical Hospital from November 2009 to November 2019.  Results: The average age was 54.67 years; 53.3% were male and all debuted in Durie-Salmon stage III. As conditioning for the transplant, 67.7% received high doses of melphalan at doses of 200 mg/m2. Cytopenias and gastrointestinal toxicity were the most common complications (93.3%). The recovery of neutrophil and platelet numbers occurred on average after 11 days, only two patients died (13.3%) and 13 (86.7%) are in complete remission with a probability of overall survival at 5 years, 77.8%.  Conclusions: Transplantation of autologous hematopoietic stem cells with the use of high doses of melphalan as conditioning in patients with multiple myeloma is a feasible procedure with a relatively low mortality and demonstrates that its inclusion in the treatment of patients considerably improves their survival expectations.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[mieloma múltiple]]></kwd>
<kwd lng="es"><![CDATA[tratamiento]]></kwd>
<kwd lng="es"><![CDATA[supervivencia]]></kwd>
<kwd lng="en"><![CDATA[multiple myeloma]]></kwd>
<kwd lng="en"><![CDATA[treatment]]></kwd>
<kwd lng="en"><![CDATA[survival]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Huff]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple Myeloma: Current Advances and Future Directions]]></article-title>
<source><![CDATA[Clinical lymphomaMyeloma &amp; Leukemia]]></source>
<year>2019</year>
<volume>19</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>255-63</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mikhael]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ismaila]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Cheung]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Costello]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Dhodapkar]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline]]></article-title>
<source><![CDATA[Journal of Clinical Oncology]]></source>
<year>2019</year>
<volume>37</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1228-63</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moreau]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[San Miguel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sonneveld]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mateos]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Zamagni]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Avet-Loiseau]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2017</year>
<volume>28</volume>
<numero>^ssuppl_4</numero>
<issue>^ssuppl_4</issue>
<supplement>suppl_4</supplement>
</nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="">
<collab>Grupo de trabajo de la Dirección Nacional de Registros Médicos y Estadísticas de Salud del MINSAP</collab>
<source><![CDATA[Anuario Estadístico de Salud 2019. Cuba]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rajkumar]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple myeloma current treatment algorithms]]></article-title>
<source><![CDATA[Blood Cancer Journal]]></source>
<year>2020</year>
<volume>10</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[D'Souza]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Pasquini]]></surname>
<given-names><![CDATA[Zhu]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current use and trends in hematopoietic cell transplantation in the United States]]></article-title>
<source><![CDATA[Biol Blood Marrow Transplant]]></source>
<year>2017</year>
<volume>23</volume>
<page-range>1417-21</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruiz-Argüelles]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lobato-Mendizábal]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz-Argüelles]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Romano]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Arizpe-Bravo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Marín-López]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-cryopreserved unmanipulated hematopoietic peripheral blood stem cell autotransplant program: long term results]]></article-title>
<source><![CDATA[Arch Med Res]]></source>
<year>1999</year>
<volume>30</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>380-4</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="">
<collab>Centro para la Investigación Internacional de Trasplantes de Sangre y Médula Ósea</collab>
<source><![CDATA[BTM infoNet]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<collab>World Medical Association Declaration of Helsinki</collab>
<article-title xml:lang=""><![CDATA[Ethical Principles for Medical Research Involving Human Subjects]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2013</year>
<volume>310</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sonbol]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Firwana]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kolla]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Almader-Douglas]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Palmer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High-Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis]]></article-title>
<source><![CDATA[Biol Blood Marrow Transplant]]></source>
<year>2019</year>
<volume>25</volume>
<page-range>239-47</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Mink]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Adami]]></surname>
<given-names><![CDATA[HO]]></given-names>
</name>
<name>
<surname><![CDATA[Cole]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mandel]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Oken]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple Myeloma: a Review of The Epidemiologic Literature]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2007</year>
<volume>120</volume>
<numero>^sSuppl 12</numero>
<issue>^sSuppl 12</issue>
<supplement>Suppl 12</supplement>
<page-range>40-61</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Afram]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Afram]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gran]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Borg Bruchfeld]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Hussain]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real - life outcomes of daratumumab treatment]]></article-title>
<source><![CDATA[Eur J Haematol]]></source>
<year>2020</year>
<volume>105</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>196-202</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez-Cornejo]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[Nájera-Martínez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Torres-Alarcón]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Bueno]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[García-Castillo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Campos-Cortés]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de mieloma múltiple en un hospital de referencia de la Ciudad de México de 2011 a 2016]]></article-title>
<source><![CDATA[Rev Hematol Mex]]></source>
<year>2020</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>32-40</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Terpos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ntanasis-Stathopoulos]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International Myeloma Society. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting]]></article-title>
<source><![CDATA[Clinical Lymphoma, Myeloma and Leukemia]]></source>
<year>2018</year>
<volume>19</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kulkarni]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Devasia]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Korula]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fouzia]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Nisham]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
<name>
<surname><![CDATA[Samoon]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of Non-Cryopreserved Peripheral Blood Stem Cells Is Associated with Adequate Engraftment in Patients with Multiple Myeloma Undergoing an Autologous Transplant]]></article-title>
<source><![CDATA[Biol Blood Marrow Transplant]]></source>
<year>2018</year>
<volume>24</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>31-5</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jaramillo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Useche]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rosales]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Manzi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Estacio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trasplante autólogo de células madre hematopoyéticas en pacientes con diagnóstico de mieloma múltiple, experiencia en 9 años]]></article-title>
<source><![CDATA[Revista Colombiana de Cancerología]]></source>
<year>2018</year>
<volume>22</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>138-42</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahindra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hari]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fraser]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fei]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Berdeja]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis]]></article-title>
<source><![CDATA[Bone Marrow Transplant]]></source>
<year>2017</year>
<volume>52</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1616-22</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Antlanger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dust]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Reiter]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Böhm]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lamm]]></surname>
<given-names><![CDATA[WW]]></given-names>
</name>
<name>
<surname><![CDATA[Gornicec]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study]]></article-title>
<source><![CDATA[BMC Cáncer]]></source>
<year>2018</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1008</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bashir]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Parmar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Rondon]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Feasibility of autologous hematopoietic stem cell transplant in patients aged &#8805; 70 years with multiple myeloma]]></article-title>
<source><![CDATA[Leukemia &amp; lymphoma]]></source>
<year>2012</year>
<volume>53</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>118-22</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Desikan]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Mehta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Singhal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fassas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Munshi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Age is not a prognostic variable with autotransplants for multiple myeloma]]></article-title>
<source><![CDATA[Blood]]></source>
<year>1999</year>
<volume>93</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>51-4</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hassan]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Fauzi]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Husin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mustaffa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hassan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ibrahim]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autologous Peripheral Blood Stem Cell Transplantation Among Lymphoproliferative Disease Patients: Factors Influencing Engraftment]]></article-title>
<source><![CDATA[Oman Medical Journal]]></source>
<year>2019</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>34-43</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sekine]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ziegelmann]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Manica]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[da Fonte Pithan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sosnoski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Morais]]></surname>
<given-names><![CDATA[VD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frontline treatment for transplant - eligible multiple myeloma: A 6474 patients network meta-analysis]]></article-title>
<source><![CDATA[Hematol Oncol]]></source>
<year>2019</year>
<volume>37</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>62-74</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kazandjian]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Landgren]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time]]></article-title>
<source><![CDATA[Clin adv Hematol Oncol]]></source>
<year>2019</year>
<volume>17</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>559-68</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soekojo]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stem-cell transplantation in multiple myeloma: how far have we come?]]></article-title>
<source><![CDATA[Ther adv Hematology]]></source>
<year>2019</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B25">
<label>25.</label><nlm-citation citation-type="journal">
<collab>Guidelines Insights</collab>
<article-title xml:lang=""><![CDATA[Multiple Myeloma, v3]]></article-title>
<source><![CDATA[J Natl Compr Can Netw]]></source>
<year>2016</year>
<volume>14</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>389-400</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Jo]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
<name>
<surname><![CDATA[Ahn]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Ahn]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frontline therapy for newly diagnosed patients with multiple myeloma]]></article-title>
<source><![CDATA[Blood Research]]></source>
<year>2020</year>
<volume>55</volume>
<numero>S1</numero>
<issue>S1</issue>
</nlm-citation>
</ref>
<ref id="B27">
<label>27.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sarmiento]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lira]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ocqueteau]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jara]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Experiencia de 22 años de trasplante autólogo de células hematopoyéticas en pacientes con mieloma múltiple o amiloidosis sistémica. 1992-2014]]></article-title>
<source><![CDATA[Rev Méd Chile]]></source>
<year>2014</year>
<volume>142</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1497-501</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gopalakrishnan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[D'Souza]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fraser]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Davila]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revised International Staging System Is Predictive and Prognostic for Early Relapse (&lt; 24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biology of blood and marrow transplantation]]></article-title>
<source><![CDATA[Journal of the American Society for Blood and Marrow Transplantation]]></source>
<year>2019</year>
<volume>25</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>683-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
